- ANGLE (AIM:AGL), the specialist medtech company, has announced that the Medical University of Vienna has published further highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.

The 65 patient study demonstrated the detection of ovarian cancer at 78/80% sensitivity with 100% specificity, offering the potential for a much more effective detection of ovarian cancer than traditional techniques.

ANGLE estimates that the ovarian cancer sales potential for the Parsortix system in Europe and the United States would be in excess of £300m per annum.

Its founder and chief executive, Andrew Newland, commented: "Detection of ovarian cancer is ANGLE's first clinical application for our Parsortix system. The continued strong results from Medical University of Vienna are impressive."

At 10:19am: [LON:AGL] Angle PLC share price was +3p at 83.5p

Story provided by